Targeting MYC dependence in cancer by inhibiting BET bromodomains

The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies. However, pharmacologic inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein–DNA interactions. Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small molecule inhibitors of the BET family of chromatin adaptors. MYC transcriptional suppression was observed in the context of the natural, chromosomally translocated, and amplified gene locus. Inhibition of BET bromodomain–promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors. MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor. Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. These findings demonstrate that pharmacologic inhibition of MYC is achievable through targeting BET bromodomains. Such inhibitors may have clinical utility given the widespread pathogenetic role of MYC in cancer.

[1]  C. Hsiao,et al.  NUT Midline Carcinoma , 2011, International journal of surgical pathology.

[2]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[3]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[4]  Clifford A. Meyer,et al.  MYC regulation of a “poor-prognosis” metastatic cancer cell state , 2010, Proceedings of the National Academy of Sciences.

[5]  M. Henriksson,et al.  MYC in oncogenesis and as a target for cancer therapies. , 2010, Advances in cancer research.

[6]  K. Ozato,et al.  Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. , 2009, Molecular biology of the cell.

[7]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[8]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[9]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[10]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[11]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[12]  S. J. Flint,et al.  The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. , 2008, Molecular cell.

[13]  M. Caligiuri,et al.  A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents , 2008, Clinical Cancer Research.

[14]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[15]  Qiang Zhou,et al.  Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.

[16]  Shwu‐Yuan Wu,et al.  The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation* , 2007, Journal of Biological Chemistry.

[17]  M. Henriksson,et al.  The Myc oncoprotein as a therapeutic target for human cancer. , 2006, Seminars in cancer biology.

[18]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Danny Reinberg,et al.  Elongation by RNA polymerase II: the short and long of it. , 2004, Genes & development.

[20]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[21]  M. Eilers,et al.  Negative regulation of the mammalian UV response by Myc through association with Miz-1. , 2002, Molecular cell.

[22]  J. Massagué,et al.  Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. , 2002, Nature.

[23]  C. Dang,et al.  Translocations involving c-myc and c-myc function , 2001, Oncogene.